# AbbVie Reports Positive Phase 3 Data for Bispecific T‑Cell Engager in Multiple Myeloma

AbbVie announced positive phase 3 results for its bispecific T‑cell engager etentamig on Thursday. The trial enrolled patients with relapsed or refractory multiple myeloma. Treatment with etentamig led to improved response rates and progression‑free survival compared to current therapies.

The company disclosed the data without providing specific numerical figures or detailed analysis. Full results are expected to be presented at a future medical meeting or submitted for publication.

## Relevance to the Life Sciences

Bispecific T‑cell engagers are a class of immunotherapy that bind both a tumor antigen and a T‑cell receptor, forcing T cells to attack cancer cells. Multiple myeloma remains an incurable blood cancer, and patients who relapse after standard treatments have limited options. Positive phase 3 data supports the potential for etentamig to become a new treatment option and highlights the broader trend of engineered immune‑based therapies in oncology.

Source: [original report](https://www.fiercebiotech.com/biotech/abbvies-bispecific-t-cell-engager-shows-promise-ph-3-multiple-myeloma-trial)